Please enable JavaScript.
Coggle requires JavaScript to display documents.
TICAGRELOR (Pharmacodynamics and Pharmacokinetics (MECHANISM OF ACTION…
TICAGRELOR
Antiplatelet Agent, Cyclopentyltriazolopyrimidine
CONTRAINDICATIONS
Hypersensitivity (eg, angioedema) to ticagrelor or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage); history of intracranial hemorrhage
ADVERSE REACTIONS
As with all drugs which may affect hemostasis, bleeding is associated with ticagrelor. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents which alter hemostasis and patient susceptibility.
10%: Respiratory: Dyspnea (14%)
1% to 10%:
Cardiovascular:
ECG abnormality (ventricular pause; 2% to 6%), presyncope (≤2%), syncope (≤2%)
Central nervous system: Dizziness (5%), loss of consciousness (≤2%)
-
Hematologic & oncologic: Major hemorrhage (4%), minor hemorrhage (4%)
-
-
<1%, postmarketing, and/or case reports: Angioedema, atrioventricular block, bradycardia, gout, hypersensitivity reaction, skin rash
-